Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) Shares Outstanding (Weighted Average) (2016 - 2025)

Arcadia Biosciences' Shares Outstanding (Weighted Average) history spans 12 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 426.55% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, up 426.55%, while the annual FY2025 figure was $1.4 million, 426.55% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $1.4 million in Q4 2025 per RKDA's latest filing, roughly flat from $1.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $19.0 million in Q1 2021 to a low of $195885.0 in Q2 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $3.5 million, with a median of $1.4 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): plummeted 97.08% in 2022, then surged 426.55% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $532016.0 in 2021, then rose by 12.66% to $599389.0 in 2022, then surged by 106.37% to $1.2 million in 2023, then tumbled by 79.0% to $259817.0 in 2024, then soared by 426.55% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Shares Outstanding (Weighted Average) are $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $195885.0 (Q2 2025).